Table 2 Associations of anti-EBV antibodies with Odds ratio (OR) of gastric cancer risk
From: EBV antibody and gastric cancer risk: a population-based nested case-control study in southern China
Cases | Controls | Crude OR (95% CI) | Adjusted OR (95% CI)† | Adjusted OR (95% CI)†† | |
|---|---|---|---|---|---|
EBNA1-IgA | |||||
Negative | 16 (88.9%) | 422 (95.0%) | ref | ref | ref |
Positive | 2 (11.1%) | 22 (5.0%) | 2.59 (0.55,12.11) | 2.59 (0.55,12.13) | 2.59 (0.55,12.13) |
EBNA1-IgA, rOD | 1.98 (1.07,3.68) | 1.99 (1.07,3.70) | 1.99 (1.07,3.70) | ||
VCA-IgA | |||||
Negative | 16 (88.9%) | 418 (94.1%) | ref | ref | ref |
Positive | 2 (11.1%) | 26 (5.9%) | 2.16 (0.47,9.82) | 2.15 (0.47,9.95) | 2.15 (0.47,9.95) |
VCA-IgA, rOD | 2.63 (1.33,5.20) | 2.64 (1.33,5.23) | 2.64 (1.33,5.23) | ||
Serological risk (combination of VCA-IgA and EBNA-IgA) | |||||
Medium/Low | 15 (83.3%) | 431 (97.1%) | ref | ref | ref |
High | 3 (16.7%) | 13 (2.9%) | 6.49 (1.68,25.00) | 6.53 (1.69,25.26) | 6.53 (1.69,25.26) |